Outlook Therapeutics, Inc. announced a private placement of 714,286 shares at a price of $7 per share for the gross proceeds of $5,000,002 and accompanying warrant to purchase one and a half shares of common stock on April 15, 2024. The warrants have an exercise price of $7.70 per share of common stock and will expire on April 15, 2029. The transaction included participation from returning investor,
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.68 USD | +4.92% |
|
+5.33% | -0.95% |
03:09pm | Outlook Therapeutics Receives UK Marketing Authorization for Eye Disease Drug | MT |
Jul. 01 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to Russell Small Cap Comp Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.95% | 171M | |
+18.10% | 45.34B | |
+41.98% | 40.42B | |
-9.97% | 37.92B | |
+32.10% | 31.75B | |
-8.98% | 27.71B | |
+12.90% | 26.52B | |
+44.71% | 13.96B | |
+31.96% | 12.44B | |
-6.22% | 11.26B |
- Stock Market
- Equities
- OTLK Stock
- News Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC